Trial Profile
A Phase 1, Open-label, Single-dose, Dose-escalation, Safety, Tolerability, and PK Study of Intravitreal ANX007 in Participants With Primary Open-angle Glaucoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Oct 2019
Price :
$35
*
At a glance
- Drugs ANX 007 (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions; First in man
- Sponsors Annexon
- 09 Oct 2019 Results (n=17) presented in the Annexon media release.
- 13 Dec 2018 Status changed from recruiting to completed.
- 03 Apr 2018 Status changed from planning to recruiting.